174 related articles for article (PubMed ID: 34498983)
1. Future perspective: metabolism as a therapeutic target in acute myeloid leukemia - from Warburg to precision medicine.
Hatfield KJ; Grønningsaeter IS; Reikvam H
Curr Med Res Opin; 2021 Dec; 37(12):2107-2111. PubMed ID: 34498983
[TBL] [Abstract][Full Text] [Related]
2. Precision medicine for acute myeloid leukemia.
Lai C; Karp JE; Hourigan CS
Expert Rev Hematol; 2016 Jan; 9(1):1-3. PubMed ID: 26514194
[TBL] [Abstract][Full Text] [Related]
3. Insights on the Interplay between Cells Metabolism and Signaling: A Therapeutic Perspective in Pediatric Acute Leukemias.
Anselmi L; Bertuccio SN; Lonetti A; Prete A; Masetti R; Pession A
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872391
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.
Darwish NH; Sudha T; Godugu K; Elbaz O; Abdelghaffar HA; Hassan EE; Mousa SA
Oncotarget; 2016 Sep; 7(36):57811-57820. PubMed ID: 27506934
[TBL] [Abstract][Full Text] [Related]
5. Targeting Glutamine Metabolism as an Attractive Therapeutic Strategy for Acute Myeloid Leukemia.
Xiao Y; Hu B; Guo Y; Zhang D; Zhao Y; Chen Y; Li N; Yu L
Curr Treat Options Oncol; 2023 Aug; 24(8):1021-1035. PubMed ID: 37249801
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic landscape of acute myelogenous leukemia--moving toward personalized medicine.
Lamba G; Zaidi SK; Luebbers K; Verschraegen C; Stein GS; Rosmarin A
J Cell Biochem; 2014 Oct; 115(10):1669-72. PubMed ID: 24905899
[TBL] [Abstract][Full Text] [Related]
7. New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.
Gojo I; Karp JE
Clin Cancer Res; 2014 Dec; 20(24):6233-41. PubMed ID: 25324141
[TBL] [Abstract][Full Text] [Related]
8. Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia.
Ma J; Ge Z
Bosn J Basic Med Sci; 2021 Aug; 21(4):409-421. PubMed ID: 33577442
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia.
Zhou J; Bi C; Ching YQ; Chooi JY; Lu X; Quah JY; Toh SH; Chan ZL; Tan TZ; Chong PS; Chng WJ
J Hematol Oncol; 2017 Jul; 10(1):138. PubMed ID: 28693523
[TBL] [Abstract][Full Text] [Related]
10. Precision therapy for acute myeloid leukemia.
Yang X; Wang J
J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553
[TBL] [Abstract][Full Text] [Related]
11. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
12. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
13. Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01.
Miyamoto K; Minami Y
Int J Clin Oncol; 2019 Aug; 24(8):893-898. PubMed ID: 31111287
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia.
Ricciardi MR; Mirabilii S; Licchetta R; Piedimonte M; Tafuri A
Adv Biol Regul; 2017 Aug; 65():36-58. PubMed ID: 28549531
[TBL] [Abstract][Full Text] [Related]
16. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic targeting and personalized approaches for AML.
Roboz GJ
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):44-51. PubMed ID: 25696833
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective.
van Dijk AD; de Bont ESJM; Kornblau SM
Expert Rev Proteomics; 2020 Jan; 17(1):1-10. PubMed ID: 31945303
[No Abstract] [Full Text] [Related]
19. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.
Witte KE; Ahlers J; Schäfer I; André M; Kerst G; Scheel-Walter HG; Schwarze CP; Pfeiffer M; Lang P; Handgretinger R; Ebinger M
Pediatr Hematol Oncol; 2011 Mar; 28(2):91-9. PubMed ID: 21214408
[TBL] [Abstract][Full Text] [Related]
20. CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia.
Bajaj J; Konuma T; Lytle NK; Kwon HY; Ablack JN; Cantor JM; Rizzieri D; Chuah C; Oehler VG; Broome EH; Ball ED; van der Horst EH; Ginsberg MH; Reya T
Cancer Cell; 2016 Nov; 30(5):792-805. PubMed ID: 27908736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
